[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@AponiaAnalytics Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1816152863069925376.png) @AponiaAnalytics aponia_analytics

Several biotech companies have recently made significant announcements. TG Therapeutics reported a strong Q3 revenue of $161.7m, driven by Briumvi sales, and raised its 2025 guidance. Regeneron also posted a XX% increase in Q3 revenue to $3.68b, driven by Dupixent and Eylea HD. Additionally, Pfizer reported solid Q3 results, with a revenue of $16.7b and raised its 2025 EPS guidance.

### Engagements: XXXXX [#](/creator/twitter::1816152863069925376/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1816152863069925376/c:line/m:interactions.svg)

- X Week XXXXXX +2.20%
- X Month XXXXXXX -XX%
- X Months XXXXXXXXX +502%
- X Year XXXXXXXXX +10,029%

### Mentions: XX [#](/creator/twitter::1816152863069925376/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1816152863069925376/c:line/m:posts_active.svg)

- X Week XXX -XX%
- X Month XXXXX -XX%
- X Months XXXXXX +297%
- X Year XXXXXX +5,151%

### Followers: XXXXX [#](/creator/twitter::1816152863069925376/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1816152863069925376/c:line/m:followers.svg)

- X Week XXXXX +0.02%
- X Month XXXXX -XXXX%
- X Months XXXXX +5.20%
- X Year XXXXX +196%

### CreatorRank: XXXXXXX [#](/creator/twitter::1816152863069925376/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1816152863069925376/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[finance](/list/finance)  XXXXX% [stocks](/list/stocks)  XXXX% [cryptocurrencies](/list/cryptocurrencies)  XXXX% [countries](/list/countries)  XXXX% [exchanges](/list/exchanges)  XXXX% [technology brands](/list/technology-brands)  XXXX% [travel destinations](/list/travel-destinations)  XXXX% [vc firms](/list/vc-firms)  XXXX% [social networks](/list/social-networks)  XXXX%

**Social topic influence**
[$aclx](/topic/$aclx) #4, [$qure](/topic/$qure) #20, [$vrtx](/topic/$vrtx) #1, [$onc](/topic/$onc) 1.72%, [onc](/topic/onc) 1.72%, [$prax](/topic/$prax) 1.72%, [$lly](/topic/$lly) #33, [strong](/topic/strong) 1.38%, [$gmab](/topic/$gmab) #1, [$ions](/topic/$ions) #8

**Top accounts mentioned or mentioned by**
[@fda](/creator/undefined) [@vertexpharmas](/creator/undefined) [@usfda](/creator/undefined) [@lineagecell](/creator/undefined) [@jigarshahdc](/creator/undefined) [@aktionaer](/creator/undefined) [@who](/creator/undefined) [@cariboubios](/creator/undefined) [@avidresearch](/creator/undefined) [@uniqurenvs](/creator/undefined) [@beamtx](/creator/undefined) [@alex_jones_2028](/creator/undefined) [@mlsaini0110](/creator/undefined)

**Top assets mentioned**
[Arcellx, Inc. Common Stock (ACLX)](/topic/$aclx) [uniQure N.V. (QURE)](/topic/$qure) [Vertex Protocol (VRTX)](/topic/$vrtx) [One Cash (ONC)](/topic/$onc) [Praxis Precision Medicines, Inc. Common Stock (PRAX)](/topic/$prax) [Eli Lilly and Company (LLY)](/topic/$lly) [Ionis Pharmaceuticals, Inc. Common Stock (IONS)](/topic/$ions) [Viking Therapeutics, Inc (VKTX)](/topic/$vktx) [Novo-Nordisk (NVO)](/topic/$nvo) [CRISPR Therapeutics AG (CRSP)](/topic/$crsp) [Scholar Rock Holding Corporation Common Stock (SRRK)](/topic/$srrk) [BEAM (BEAM)](/topic/$beam) [Frontline Ltd. (FRO)](/topic/$fro) [Gilead Sciences, Inc. (GILD)](/topic/$gild) [Cytokinetics Inc. (CYTK)](/topic/$cytk) [Madrigal Pharmaceuticals, Inc. Common Stock (MDGL)](/topic/$mdgl) [IREN Limited (IREN)](/topic/$iren) [Cipher Mining Inc. Common Stock (CIFR)](/topic/$cifr) [Johnson & Johnson (JNJ)](/topic/$jnj) [Dr. Reddy's Laboratories Limited American Depositary Shares (RDY)](/topic/$rdy) [AbbVie Inc (ABBV)](/topic/$abbv) [Exelixis Inc (EXEL)](/topic/$exel) [Morgan Stanley (MS)](/topic/morgan-stanley) [Incyte Corporation (INCY)](/topic/$incy) [Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX)](/topic/$rxrx) [Oscar Health, Inc. (OSCR)](/topic/$oscr) [Natera, Inc. Common Stock (NTRA)](/topic/$ntra) [Reddit, Inc. (RDDT)](/topic/$rddt) [Vertiv Holdings Co (VRT)](/topic/$vrt)
### Top Social Posts
Top posts by engagements in the last XX hours

"$BEAM 🦉 Beam shares new risto-cel data showing strong lasting boosts in fetal hemoglobin for XX sickle-cell patients. And after treatment patients recover quickly and avoid severe crises"  
[X Link](https://x.com/AponiaAnalytics/status/1997375344257511627)  2025-12-06T18:39Z 5118 followers, XXX engagements


"$GMAB 🦉 Genmab reports that epcoritamab helped many first-line lymphoma patients reach remission in long-term follow-up. And elderly patients on monotherapy also responded well as ASH data point to earlier-line potential"  
[X Link](https://x.com/AponiaAnalytics/status/1997376720098230282)  2025-12-06T18:44Z 5118 followers, XXX engagements


"$SNDX $VRTX $CRSP"  
[X Link](https://x.com/AponiaAnalytics/status/1997673416107704513)  2025-12-07T14:23Z 5118 followers, XXX engagements


"$GILD $ACLX 🦉 Anito-cel steals the spotlight with a XX% ORR and XX% CR in tough myeloma cases and safety stays steady. Since PFS and OS keep rising Kite and Arcellx now point to a potential 2026 launch"  
[X Link](https://x.com/AponiaAnalytics/status/1997684991413895258)  2025-12-07T15:09Z 5118 followers, XXX engagements


"$GMAB 🦉 Genmab reports EPKINLY + R2 cut progression risk by XX% and hit a XX% ORR in R/R FL. Since CR reached XX% and results hit The Lancet the combo now stands as a newly approved second-line option"  
[X Link](https://x.com/AponiaAnalytics/status/1997685541769552193)  2025-12-07T15:12Z 5118 followers, XXX engagements


"$ACLX #form4 🦉 Arcellx $ACLX CFO Michelle Gilson sold 5364 shares at an average of $XXXXX under a pre-set 10b5-1 plan leaving 8466 shares held directly. Transaction filed Oct XX 2025"  
[X Link](https://x.com/AponiaAnalytics/status/1978611707581718923)  2025-10-15T23:59Z 5120 followers, XXX engagements


"$ONC 🦉BeOne Medicines Q325 Takeaways Blowout quarter: revenue $1.41B (+41% YoY) on BRUKINSA $1.0B (+51%); TEVIMBRA $191M (+17%). Gross margin XXXX% (300 bps) on richer BRUKINSA mix/productivity. Operating leverage visible: GAAP OpInc $163M vs $120M YoY; GAAP EPS/ADS $1.09; non-GAAP EPS/ADS $XXXX. Free cash flow $354M; cash to $4.11B (helped by financing and Royalty Pharma deal; note new $885M royalty liability). Opex grew 1116% but SG&A fell to XX% of sales (vs 46%)"  
[X Link](https://x.com/AponiaAnalytics/status/1986469284240134519)  2025-11-06T16:22Z 5119 followers, XXX engagements


"$IONS 🦉At AHA 2025 $IONS unveiled Phase X CORE/CORE2 data showing olezarsen cut triglycerides by up to XX% and reduced acute pancreatitis events by XX% the first therapy ever to do so in sHTG. #newsrelease"  
[X Link](https://x.com/AponiaAnalytics/status/1987222101707596149)  2025-11-08T18:14Z 5119 followers, XXX engagements


"$IONS 🦉Ionis reported Phase X CORE and CORE2 trials of olezarsen cut triglycerides by up to XX% and reduced acute pancreatitis events by XX% in severe hypertriglyceridemia. FDA filing expected by year-end with 2026 PDUFA target. #form8K #FDA"  
[X Link](https://x.com/AponiaAnalytics/status/1987890753511854386)  2025-11-10T14:31Z 5119 followers, XXX engagements


"$SRRK 🦉 Scholar Rock filed an 8-K reporting Q3 results with a $102.2M net loss and $369.6M in cash. The company also outlined 2026 BLA resubmission plans for apitegromab. #form_8K"  
[X Link](https://x.com/AponiaAnalytics/status/1989381323811864683)  2025-11-14T17:14Z 5117 followers, XXX engagements


"$ONC 🦉 BeOne Medicines reported Phase X results showing ZIIHERA plus TEVIMBRA and chemo delivered significant PFS and OS gains over trastuzumab. And both ZIIHERA regimens beat the control arm supporting submissions planned for 2026"  
[X Link](https://x.com/AponiaAnalytics/status/1990513241173471311)  2025-11-17T20:11Z 5118 followers, XXX engagements


"$ONC 🦉 BeOne highlights six-year BRUKINSA survival gains in CLL while early sonrotoclax data show rapid responses in tough MCL. And new BTK degrader results broaden its reach across relapsed blood cancers. #pressrelease #cancer"  
[X Link](https://x.com/AponiaAnalytics/status/1991558063741104638)  2025-11-20T17:23Z 5118 followers, XXX engagements


"$ONC 🦉 This Pharma Stock Owned By Top Fund Flirts With Entry As Earnings Surge 452%. BeOne Medicines surged in 2025 as Brukinsa revenue jumped XX% to $1.04B. EPS soared XXX% while Ziihera advanced after strong Phase X data"  
[X Link](https://x.com/AponiaAnalytics/status/1991934642212294686)  2025-11-21T18:20Z 5118 followers, XXX engagements


"$ONC 🦉 Director Corazon Sanders filed to sell 2627 shares for about $896K after exercising options on Nov. XX. She also reported a prior 2665-share sale in September. #form_144"  
[X Link](https://x.com/AponiaAnalytics/status/1994161078352179258)  2025-11-27T21:47Z 5118 followers, XXX engagements


"$VRTX $CRSP"  
[X Link](https://x.com/AponiaAnalytics/status/1995186607230455983)  2025-11-30T17:42Z 5118 followers, XXX engagements


"$VKTX $GPCR"  
[X Link](https://x.com/AponiaAnalytics/status/1995187609203626073)  2025-11-30T17:46Z 5121 followers, XXX engagements


"$IONS 🦉 Ionis director Joseph Wender filed to sell 33.6k shares valued at $2.50M following prior October sales under a 10b5-1 plan. The amendment updates Table I details from the earlier filing. #form_144"  
[X Link](https://x.com/AponiaAnalytics/status/1995922160854954070)  2025-12-02T18:25Z 5120 followers, XXX engagements


"$NWBO #nwbo"  
[X Link](https://x.com/AponiaAnalytics/status/1995923459872821624)  2025-12-02T18:30Z 5120 followers, XXX engagements


"$OVID 🦉 Ovid named neurologist Petra Kaufmann as chief medical officer. She brings FDA NIH and industry experience including work on Zolgensma. She will guide development of OV329 and the companys KCC2 activators"  
[X Link](https://x.com/AponiaAnalytics/status/1995954301907489089)  2025-12-02T20:32Z 5120 followers, XXX engagements


"$CYTK 🦉 CYTK directors reported 12/1 sales: Harrington sold 2150 shares at $XXXX while Kaye exercised 28064 options and sold them at $XXXXX. Kaye now holds 9977 shares. #form_4"  
[X Link](https://x.com/AponiaAnalytics/status/1995955937455337797)  2025-12-02T20:39Z 5121 followers, XXX engagements


"$SRRK 🦉 Scholar Rock said Catalent Indiana received an FDA warning letter linked to Julys inspection. The company still targets its apitegromab BLA resubmission and 2026 U.S. launch. #form_8K"  
[X Link](https://x.com/AponiaAnalytics/status/1995959230319525933)  2025-12-02T20:52Z 5120 followers, XXX engagements


"$CYTK 🦉 Director John Henderson exercised 8750 options at $XX and sold the same number at $XXXXX under a 10b5-1 plan leaving 74578 direct shares plus XX held by spouse"  
[X Link](https://x.com/AponiaAnalytics/status/1996185209273045125)  2025-12-03T11:50Z 5119 followers, XXX engagements


"$LQDA 🦉 Liquidia CFO/COO Kaseta exercised 2343 RSUs and sold 1166 shares at $XXXXX. He now holds 353823 shares including large unvested RSU blocks. #form_4"  
[X Link](https://x.com/AponiaAnalytics/status/1996190202839371814)  2025-12-03T12:10Z 5121 followers, XXX engagements


"$LQDA 🦉 Liquidia CHRO Krepp sold XXX shares at $XXXXX to cover RSU taxes and now holds 141218 shares including sizable unvested RSU grants. #form_4"  
[X Link](https://x.com/AponiaAnalytics/status/1996190758408442110)  2025-12-03T12:12Z 5121 followers, XXX engagements


"$LQDA 🦉 Liquidia GC Schundler exercised 2343 RSUs and sold 1072 shares at $XXXXX leaving 577288 direct shares plus 14500 held by spouse. #form_4"  
[X Link](https://x.com/AponiaAnalytics/status/1996191102723125661)  2025-12-03T12:13Z 5119 followers, XXX engagements


"$ABBV $ABVX"  
[X Link](https://x.com/AponiaAnalytics/status/1996685544009666698)  2025-12-04T20:58Z 5120 followers, XXX engagements


"$VKTX $MDGL $LLY"  
[X Link](https://x.com/AponiaAnalytics/status/1996685711790202980)  2025-12-04T20:59Z 5120 followers, XXX engagements


"$PRAX 🦉 Praxis granted 3594 inducement RSUs to six new hires. The awards vest over four years and were issued under the 2024 Inducement Plan for Nasdaq Rule 5635(c)(4)"  
[X Link](https://x.com/AponiaAnalytics/status/1996688485764272399)  2025-12-04T21:10Z 5118 followers, XXX engagements


"$EXEL 🦉 Exelixis set December XX for a webcast R&D Day. The event will review oncology pipeline progress and it will outline plans for next-generation cancer franchises"  
[X Link](https://x.com/AponiaAnalytics/status/1996688784314839501)  2025-12-04T21:11Z 5119 followers, XXX engagements


"$TBPH 🦉 Theravance officer Rhonda Farnum filed to sell 31067 shares worth $582.5K on Dec. X through Morgan Stanley under a 10b5-1 plan. Shares derive from multiple RSU grants vested between 20212025. #form_144"  
[X Link](https://x.com/AponiaAnalytics/status/1996689537645343155)  2025-12-04T21:14Z 5121 followers, XX engagements


"$INCY 🦉 Incyte brings in Richard Hoffman as its new top lawyer. The company grants him 43301 stock options at $XXXXXX alongside 9466 RSUs. And it adds 23665 performance shares tied to three-year TSR"  
[X Link](https://x.com/AponiaAnalytics/status/1996690407237820781)  2025-12-04T21:17Z 5118 followers, XX engagements


"$MDGL 🦉 CFO Mardi Dier exercised 4173 options at $XXXXXX and sold multiple blocks between $570$596 leaving 10440 shares. One 10b5-1 plan governed the trades. #form_4"  
[X Link](https://x.com/AponiaAnalytics/status/1996696237291061321)  2025-12-04T21:40Z 5119 followers, XXX engagements


"$RXRX 🦉 Director Blake Borgeson sold 220000 Class A shares at $XXXX under a 10b5-1 plan. His direct holdings now total 6869863 shares. #form_4"  
[X Link](https://x.com/AponiaAnalytics/status/1996700854989336953)  2025-12-04T21:59Z 5121 followers, XXX engagements


"$OSCR 🦉 CLO Adam McAnaney sold 1852 shares at a $XXXXX average under a 10b5-1 tax-withholding plan. He now holds 179241 Class A shares directly. #form_4"  
[X Link](https://x.com/AponiaAnalytics/status/1996721443447447949)  2025-12-04T23:21Z 5121 followers, XXX engagements


"$NVO #Denmark"  
[X Link](https://x.com/AponiaAnalytics/status/1996999290128834681)  2025-12-05T17:45Z 5118 followers, XXX engagements


"$NTRA 🦉 Natera snaps up Foresight to bring its ultra-sensitive MRD tech in-house. The $275M stock deal also adds proven lymphoma tools and together the teams broaden Nateras tumor testing reach"  
[X Link](https://x.com/AponiaAnalytics/status/1997001180954636303)  2025-12-05T17:52Z 5121 followers, XX engagements


"$SOFI $RDDT $VEEV $PSTG"  
[X Link](https://x.com/AponiaAnalytics/status/1997002774337216934)  2025-12-05T17:58Z 5117 followers, XXX engagements


"$KALA 🦉 Kala priced a direct sale of 900k shares and 9.1M pre-funded warrants at $X raising $9.2M before expenses. Net proceeds will partly repay a XX% loan and payments owed to Oxford. #form_424B5"  
[X Link](https://x.com/AponiaAnalytics/status/1997006417174163577)  2025-12-05T18:13Z 5118 followers, XXX engagements


"$MIRM 🦉 Janus Henderson reported 5.45M Mirum shares held with shared voting and dispositive power equal to XXXX% of the float. Subsidiaries advise portfolios holding 5.31M shares. #form_13G/A"  
[X Link](https://x.com/AponiaAnalytics/status/1997009180771897394)  2025-12-05T18:24Z 5117 followers, XX engagements


"$PRAX $XBI #Biotechs"  
[X Link](https://x.com/AponiaAnalytics/status/1997009376461443118)  2025-12-05T18:25Z 5119 followers, XXX engagements


"$IREN $CIFR #AI"  
[X Link](https://x.com/AponiaAnalytics/status/1997363551816581513)  2025-12-06T17:52Z 5121 followers, XXX engagements


"$RGNX 🦉 REGENXBIO to host Q3 2025 earnings call on November X at X a.m. ET to review financial results and operational progress across its AAV gene therapy pipeline. #newsrelease"  
[X Link](https://x.com/AponiaAnalytics/status/1983544214022705535)  2025-10-29T14:39Z 5119 followers, XXX engagements


"$VRTX 🦉Vertexs povetacicept cut proteinuria by XX% in IgA nephropathy and XX% in membranous nephropathy at XX weeks with stable kidney function. BLA filing set for 2025 as Phase X RAINIER fully enrolled. #pressrelease"  
[X Link](https://x.com/AponiaAnalytics/status/1987284880716132818)  2025-11-08T22:23Z 5119 followers, XXX engagements


"$GMAB 🦉Genmab plans $2.5B in new notes$1.5B secured due 2032 and $1B unsecured due 2033plus a $2B term loan B to finance its $Merus acquisition. Proceeds will cover purchase and related costs. #newsrelease"  
[X Link](https://x.com/AponiaAnalytics/status/1987897468449644891)  2025-11-10T14:57Z 5119 followers, XXX engagements


"$RGNX 🦉 REGENXBIO filed a shelf registration to offer up to $300M in mixed securities. The S-3 enables future sales through various structures. And it keeps flexibility to raise capital as needed. #form_S-3"  
[X Link](https://x.com/AponiaAnalytics/status/1993798854207262829)  2025-11-26T21:47Z 5119 followers, XX engagements


"$QURE #FDA 🦉 uniQure says FDA doubts its early AMT-130 data which stalls a possible BLA. So the team moves to secure a new meeting in early 2026 and it emphasizes the urgency for families living with Huntingtons disease"  
[X Link](https://x.com/AponiaAnalytics/status/1996699909626466618)  2025-12-04T21:55Z 5118 followers, XXX engagements


"$QURE 🦉 FDA said Phase I/II AMT-130 data likely wont support a BLA and uniQure will seek a follow-up meeting in early 2026. The update was disclosed under Item XXXX. #form_8K"  
[X Link](https://x.com/AponiaAnalytics/status/1996700469490864508)  2025-12-04T21:57Z 5118 followers, XXX engagements


"$IREN $CIFR $CLSK $BITF"  
[X Link](https://x.com/AponiaAnalytics/status/1997004343128531194)  2025-12-05T18:05Z 5119 followers, XXX engagements


"$XOMA $MURA 🦉 XOMA closes its court-sanctioned deal to buy all Mural shares. Mural holders receive $XXXXX per share as trading ends on Nasdaq. And the company now moves toward delisting and deregistration"  
[X Link](https://x.com/AponiaAnalytics/status/1997007782332322054)  2025-12-05T18:18Z 5119 followers, XX engagements


"$XOMA 🦉 XOMA closed its $2.035-per-share cash acquisition of Mural after Irish court approval. All Mural equity awards were canceled and cashed out at the deal price. #form_8K"  
[X Link](https://x.com/AponiaAnalytics/status/1997008794736341448)  2025-12-05T18:22Z 5119 followers, XX engagements


"$BEAM @BeamTx"  
[X Link](https://x.com/AponiaAnalytics/status/1997364397598007376)  2025-12-06T17:55Z 5120 followers, XXX engagements


"$NVO #Healthify 🦉 Healthify signs its first deal with Novo Nordisk India. Then it begins offering coaching tied to GLP-1 weight-loss drugs. And it plans similar global partnerships as subscriptions surge"  
[X Link](https://x.com/AponiaAnalytics/status/1997367341793820871)  2025-12-06T18:07Z 5119 followers, XXX engagements


"$ACLX 🦉 Arcellx held its FDA pre-BLA meeting for anito-cel reaffirming a 2026 launch plan. Updated Phase X iMMagine-1 multiple myeloma data to be presented at ASH 2025. #newsrelease #myeloma"  
[X Link](https://x.com/AponiaAnalytics/status/1985413897948467335)  2025-11-03T18:28Z 5120 followers, XXX engagements


"$GMAB 🦉 Genmab closed $2.5B in notes. It combined XXXX% 2032 secured and XXXX% 2033 unsecured debt with new loan facilities. The funds will support its Merus acquisition"  
[X Link](https://x.com/AponiaAnalytics/status/1996687671780106702)  2025-12-04T21:06Z 5118 followers, XXX engagements


"$IONS 🦉 Joseph Wenders trust sold 28000+ shares at $80.66$81.23 leaving 36035 indirect shares and 16000 direct shares. Sales were under a 10b5-1 plan. #form_4"  
[X Link](https://x.com/AponiaAnalytics/status/1996696630293098676)  2025-12-04T21:42Z 5120 followers, XXX engagements


"$PRAX $VNDA $CAPR $BMEA"  
[X Link](https://x.com/AponiaAnalytics/status/1996999751372345526)  2025-12-05T17:46Z 5118 followers, XXX engagements


"$VKTX $PTGX $IDYA"  
[X Link](https://x.com/AponiaAnalytics/status/1997001289553543186)  2025-12-05T17:53Z 5120 followers, XXX engagements


"$AXSM 🦉 Axsomes CEO exercised expiring options at $XXXX and sold 79973 shares at $144148 leaving 7229 direct shares. The filing also shows 7.34M shares held indirectly. #form_4"  
[X Link](https://x.com/AponiaAnalytics/status/1997005341725262185)  2025-12-05T18:09Z 5118 followers, XXX engagements


"$URGN 🦉 UroGen grants RSUs to XX new hires. The awards cover up to 32500 shares and vest over three years. And they support commercialization of Jelmyto and ZUSDURI"  
[X Link](https://x.com/AponiaAnalytics/status/1997007458863112282)  2025-12-05T18:17Z 5118 followers, XXX engagements


"$ACLX 🦉 T. Rowe Price reported 9.6M Arcellx shares with 9.3M sole voting power representing XXXX% of the float. The firm filed as an investment adviser under Rule 13d-1(b). #form_13G/A"  
[X Link](https://x.com/AponiaAnalytics/status/1997008379345260623)  2025-12-05T18:21Z 5118 followers, XXX engagements


"$NKTR $IRON $MGNX"  
[X Link](https://x.com/AponiaAnalytics/status/1997365760272855216)  2025-12-06T18:01Z 5118 followers, XXX engagements


"$JNJ 🦉 J&J reports that CARVYKTI kept XX% of standard-risk myeloma patients treatment-free XXX years after a single infusion. And earlier use showed stronger immune fitness linking it to longer survival"  
[X Link](https://x.com/AponiaAnalytics/status/1997377085287899447)  2025-12-06T18:46Z 5120 followers, XXX engagements


"$GILD $ACLX $JNJ $LEGN #ASH25"  
[X Link](https://x.com/AponiaAnalytics/status/1997713395123159081)  2025-12-07T17:02Z 5118 followers, XXX engagements


"$VRTX #Vertex $CRSP"  
[X Link](https://x.com/AponiaAnalytics/status/1997364215921746019)  2025-12-06T17:55Z 5118 followers, XXX engagements


"$VRTX 🦉 Vertex shares big news as CASGEVY shows strong results in children as young as five. And the company now prepares global filings for 1H26 while adult data remain solid"  
[X Link](https://x.com/AponiaAnalytics/status/1997374860280922489)  2025-12-06T18:37Z 5118 followers, XXX engagements


"$ACLX #myeloma 🦉 Arcellx posted XX% ORR and XX% CR/sCR in its Phase X myeloma trial while 12-month PFS hit 82%. And since no delayed neurotoxicity surfaced the company reaffirmed its 2026 launch plan"  
[X Link](https://x.com/AponiaAnalytics/status/1997680566616076366)  2025-12-07T14:52Z 5118 followers, XXX engagements


"$PRME 🦉 Prime Medicine reports NEJM data showing PM359 restored neutrophil function and clinical stability in two CGD patients. Since no safety issues emerged the readout marks the first human proof of Prime Editing"  
[X Link](https://x.com/AponiaAnalytics/status/1997686343464595504)  2025-12-07T15:15Z 5118 followers, XXX engagements


"$REGN 🦉 Lynozyfics first-line myeloma mono posts XX% VGPR+ and XX% MRD-neg in Phase 1/2; clean safety so far ASH spotlight and a Dec XX Roundtable hints at bigger frontline ambitions"  
[X Link](https://x.com/AponiaAnalytics/status/1997782308246434226)  2025-12-07T21:36Z 5118 followers, XXX engagements